B-cell lymphoma was the predominant type, seen in 42 of 45 cases (93.3%).
其中B细胞性淋巴瘤是最常见的病理类型，占93.3%（42/45）。
The cancer vaccines rely on a biological quirk of follicular B-cell lymphoma, which is a type of non-Hodgkin's lymphoma.
滤泡性B细胞淋巴瘤是一种非霍奇金淋巴瘤，肿瘤疫苗是治疗是根据肿瘤细胞的生物学特殊性。
Objective to observe the effect and toxicity of rituximab and CHOP regimen (R-CHOP) in the treatment of initially diagnosed diffuse large B-cell lymphoma.
目的观察利妥昔单抗联合CHOP方案(R - CHOP)治疗初治弥漫大B细胞型淋巴瘤的疗效以及毒副反应。
Conclusions Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.
结论弥漫性大B细胞性淋巴瘤治疗后生存期可通过肿瘤微环境中的免疫细胞、纤维化、血管形成的差异而影响。
BRISH light chain restriction (LCR) results were concordant with FCM in 108 (99%) of 109 evaluable cases. Additional small B-cell lymphoma cohorts were successfully evaluated.
在109例可评价的病例中，有108例(99%)BRISH检测轻链限制性(LCR)的结果与流式细胞仪一致，并成功评估了另外的小B细胞淋巴瘤病例组。
PURPOSE: the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
背景：目前，弥漫大b细胞性淋巴瘤(DLBCL)的标准治疗方案为利妥昔单抗联合CHOP方案化疗(R - CHOP)。
Conclusions: the combination of MabThera and CEOP regimen had high efficacy with mild toxicity in the treatment of aggressive B-cell lymphoma, hopefully may become the standard treatment.
结论：利妥昔单抗联合CEOP方案治疗侵袭性B细胞淋巴瘤疗效高而不良反应轻，有望成为标准治疗。
Conclusions the treatment effectiveness in newly diagnosed diffuse large-B-cell lymphoma in the elderly has been improved by an individual treatment plan according to evidence-based methods.
结论采用循证医学的方法为初治的老年弥漫性大B细胞淋巴瘤患者制定化疗方案可有效提高治疗效果。
Determined that patients with diffuse large B cell lymphoma had high serum levels of miR-21, which associated with increased relapse-free survival 3. Around the same time, Mitchell et al.
Lawrie等人证实，弥漫性大B细胞淋巴瘤的病人的血清mir - 21水平很高，后者与增高的不复发存活率密切相关。
The postoperative pathology of all the patients were non Hodgkin's lymphoma, 8 were B cell type, 2 mixed cell type and 1 T cell type.
术后病理结果均为非何杰金恶性淋巴瘤，其中B细胞型8例，混合细胞型2例，T细胞型1例。
The frequency of splenomegaly in nodular type NHLBMI was significantly higher than that in any other type. Nodular type NHLBMI occurred mainly in B cell lymphoma.
结节型侵犯伴脾肿大者显著高于其他型，结节型者主要为BNHLBMI，表明NHLBMI伴脾肿大与淋巴瘤表型有关。
The pathological diagnosis were mainly B cell lymphoma.
病理类型以B细胞淋巴瘤多见。
Occasionally, CD5 antigen is also expressed on a subset of B cells. Mantle cell lymphomas (same as diffuse centrocytic lymphomas) are CD5+ while the follicle center cell lymphoma are CD5-.
外套层细胞淋巴瘤常常为CD5阳性表达，而滤泡中心性淋巴瘤常为阴性。
Histologically, 5 of 9 cases were polymorphoral(peripheral) T cell lymphoma, in the rest 4 of B cell lymphoma, 2 were lymphoplasmacytoid and the other 2 were small cell type.
组织学上多形T细胞淋巴瘤5例，B细胞淋巴瘤4例，其中淋巴浆细胞样型和小细胞性各2例。
Differential diagnosis of CBCL between cutaneous B-cell pseudolymphoma and cutaneous genuine histiocytic lymphoma is discussed.
并将各亚型与皮肤B细胞性假性淋巴瘤及组织细胞性淋巴瘤进行鉴别。
The invention also provides methods for detecting IRTA-2, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
本发明还提供了检测irta - 2的方法，以及治疗包括非何杰金氏淋巴瘤在内的各种B细胞恶性肿瘤的方法。
Results All the 11cases were B-cell type lymphoma, and male patients were more common.
结果11例胃MALT淋巴瘤全部示B细胞性淋巴瘤，且男性多于女性。
Conclusion Most cases were B-cell type lymphoma with low-grade malignancy.
结论11例胃malt淋巴瘤中大多数示低度恶性B细胞性淋巴瘤。
Epratuzumab and 90Y Epratuzumab for B cell non-Hodgkin lymphoma.
依帕珠单抗和钇-90标记的依帕珠单抗，用于B细胞非霍奇金淋巴瘤。
Epratuzumab and 90Y Epratuzumab for B cell non-Hodgkin lymphoma.
依帕珠单抗和钇-90标记的依帕珠单抗，用于B细胞非霍奇金淋巴瘤。
应用推荐